Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

Clinical & Translational Science Collaborative (CTSC)

The CTSC Annual Pilot Program is for researchers to conduct innovative translational research projects focused on the invention, preclinical development and/or first in man studies of novel therapeutic agents, biomedical devices, and diagnostics designed to address unmet clinical needs. Funding is intended to facilitate development of enabling technologies; new therapeutic, diagnostic or outcomes assessment approaches and/or device; novel cross-disciplinary collaborative programs; and promote research in the community.

Research which may create intellectual property is encouraged. If funding would enhance an existing non-federally funded project or enable a proposal to a federal agency for use of CTSC and CCTRP resources, the application would be considered. This pilot has few restrictions and allows for the hiring of personnel. Researchers new to clinical research, clinical research scholars, or experienced researchers who are moving into a new area of research are strongly encouraged to apply.

Available Funds: Up to $50,000 per project for up to one year of support.

Deadline for Letter of Intent: January 15, 2015.

For questions contact:
CTSC Pilot Program Office: CTSC-Pilot-Coordinator@case.edu

For more information, visit the CTSC website.

 
National Museum of Women in the Arts (NMWA)

Founded in 1987, the National Museum of Women in the Arts is the only major museum in the world solely dedicated to recognizing the creative contributions of women. By bringing to light remarkable women artists of the past while also promoting the best women artists working today, the museum directly addresses the gender imbalance in the presentation of art in the U.S. and abroad, thus assuring great women artists a place of honor now and into the future.

The Suzanne and James Mellor Prize of $50,000 is awarded annually to the author of the best proposal for a scholarly book on an individual woman artist or subject related to the mission of NMWA.

The purpose of the award is to encourage the highest quality scholarship on women artists from any time period or nationality and to enhance the role of the museum in shaping scholarly dialogue on women in the arts.

Deadline: Jan. 1, 2015

The official announcement and description of this opportunity may be found on the NMWA website.

 

Department of Defense

The Fiscal Year 2014 (FY14) Defense Appropriations Act provides research funding for the peer reviewed programs managed by the Department of Defense (DOD) office of Congressionally Directed Medical Research Programs (CDMRP).

Gulf War Illness Research Program (GWIRP)
Innovative Treatment Evaluation Award 2

Breast Cancer Research Program (BCRP)
Breakthrough Award Funding Levels 1 and 2
Breakthrough Award Funding Levels 3 and 4

 
The Cleveland Area Reliant IRB Review Process

The Cleveland Area Reliant Institutional Review Board (IRB) Review process includes participation by the Case Western Reserve University (CWRU) Social, Behavioral, and Educational Research (SBER) IRB, the Cleveland Clinic (CC) IRB, MetroHealth Medical Center (MHMC) IRB, and University Hospitals Case Medical Center (UHCMC) IRB. The process relies on executed IRB Authorization Agreements (IAA) between the institutions. These agreements document that all applicable human research subjects protection considerations will be made by one Institutional Review Board (IRB), which will be deemed the IRB of record. The IRBs of the other Cleveland area institutions will accept the approval of the IRB of record through the Reliant Review process. The goal is to eliminate duplication of effort and multiple applications for submission of the same protocol, and to encourage scientific collaboration among the affiliated institutions.

What types of studies are eligible for the Reliant Review Process?
Any type of human research study could be eligible for the Reliant Review process. These include but are not limited to investigator-initiated, federally-funded, foundation-supported, industry-sponsored, and non-funded studies.

The fundamental requirement is that a collaborating investigator must be named at each site where the research will occur. It is important for the Principal Investigator at the lead study site to work with the IRB of record throughout the Reliant Review Process to initiate acceptance of IRB approval at each collaborating site.

For further information, contact Kim Volarcik at (216) 368-0134 or kav6@case.edu.

 
The Ohio Clinical Trial Collaborative (OCTC)

The Ohio Clinical Trial Collaborative OCTC is developing partnerships with the drug industry to include Biotech and Pharmaceutical industries to perform clinical drug trials phase I-4. The OCTC is a network of Ohio based hospitals led by working groups in areas such as neuro oncology, pediatrics, infectious disease, and neuroscience. The OCTC was launched at the BIO2014 which was attended by 15,000 biotech and pharmaceutical executives in San Diego resulting in numerous leads for potential drug trials.

The OCTC has plans to attend additional biotech and pharmaceuticals shows. The OCTC is looking for additional working groups interested in developing a sell sheet that can then be searched on the World Wide Web and will begin sales and marketing activities to identify opportunities with industry. If there are companies that individuals would like OCTC to target, the group welcomes that feedback.

Review the OCTC working website at: http://ohioclintrials.org.

Contact Joe Peter at 216-702-5314 for more information.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.